The new device enables the treatment of patients in a clinical or home setting. Credit: Albina Gavrilovic / Shutterstock.com.

Zynex has submitted a 510(k) application seeking approval from the US Food and Drug Administration (FDA) for its M-Wave Neuromuscular Electrical Stimulation (NMES) device.

The M-Wave is intended to replace its predecessor, the E-Wave muscle stimulation device, which has been fundamental in NMES treatments across the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The E-Wave has been considered a significant device on the market for more than two decades, while the M-Wave has a more modern design with the same ease of use.

Zynex’s new device aims to improve the way individuals handle their neuromuscular conditions.

It comes with a user-friendly design and advanced features, enabling it to treat patients in a clinical or home setting.

Furthermore, the device’s compact and lightweight design enables portability and easy integration into the recovery routines of the patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are excited to introduce the M-Wave, a device that showcases our ongoing commitment to improving the lives of patients dealing with neuromuscular conditions,” said Zynex Medical CEO Thomas Sandgaard.

“The M-Wave will be another game-changer, providing a more effective and user-friendly treatment option for patients and a valuable tool for healthcare professionals.

“I believe that this next-generation device will be able to build upon the need for customisable NMES treatments in clinical and home settings.”

Zynex is involved in the development, manufacturing, marketing and sale of medical devices for pain management and rehabilitation.

The company also offers non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals.